UNSPSC 51332304: Oxiperomide

This classification denotes an antiparkinsonian agent with the molecular formula C20H23N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WRO75M6RW2, chemically known as 2h-benzimidazol-2-one, 1,3-dihydro-1-(1-(2-phenoxyethyl)-4-piperidinyl)- but generally known as oxiperomide, which bears US NIH Compound Identifier 68634. European Medicines Agency schedules Oxiperomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09534MIG.

UNSPSC 51332304 Oxiperomide is a Commodity code, but the recent state and local opportunities posted against it do not align with the code's nominal pharmaceutical scope—instead, they reflect procurement of naloxone kits, generic multi-source pharmaceuticals, and over-the-counter products through cooperative purchasing and direct-to-manufacturer programs. The work being solicited is acquisition and distribution of pharmaceutical products, including emergency medications, generics, and OTC items, with delivery and supply-chain management. The issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving participating state and local government facilities). The code shows little recent activity aligned with its actual definition; the tagging appears to reflect a classification mismatch rather than sustained procurement of oxiperomide specifically.

Recent opportunities span Florida, Texas, and the Minnesota cooperative purchasing region (including Oregon). Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with bids due July 26, 2023 (note: this date is retroactive and appears erroneous in the source). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, as exploratory market research for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, with no formal bid deadline or award value. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026, and contract effectiveness July 1, 2026. None of these opportunities target oxiperomide as a line item or primary commodity.